GlassScriptPhysician profile
Dierdre A Fogle
NPI 1245227024
$2,966.91
in general payments reported to CMS, 2019-2025
19 companies · $476 in 2025
The $476 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.24 · 2020: $392 · 2021: $1,116 · 2022: $206 · 2023: $267 · 2024: $421 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,165.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,287.90 | 2019-2025 | Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $362.83 | 2019-2025 | Acuvue |
| Coopervision INC. | $248.18 | 2019-2025 | Misight Contact Lens, Biofinity Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $241.35 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Dompe US, INC. | $176.51 | 2021-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $121.37 | 2019-2023 | |
| Astellas Pharma US INC | $120.89 | 2024 | Izervay |
| Sun Pharmaceutical Industries INC. | $81.37 | 2019-2023 | Cequa |
| Biotissue Holdings INC. | $53.79 | 2021-2024 | |
| Oyster Point Pharma, INC. | $45.60 | 2023-2025 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $44.66 | 2024-2025 | Vevye |
| Allergan, INC. | $42.57 | 2020-2021 | |
| Notal Vision, INC. | $37.24 | 2021-2022 | |
| Shire North American Group INC | $25.00 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $16.42 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $15.00 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.73 | 2021 | |
| Kala Pharmaceuticals, INC. | $12.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dierdre Fogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.